https://endpts.com/pfizer-ceo-says-its-back-to-basics-after-painful-2023-for-investors/

Interesting comments below 

Obesity, cancer and what’s next 

Bourla said the company’s run of significant acquisitions was on pause, and it would focus primarily on licensing deals that will give it access to earlier-stage, lower-cost assets. That could include earlier-stage assets for the treatment of obesity, after the drugmaker reported disappointing data last month from it’s oral GLP-1, danuglipron.